CONVERT PHARMACEUTICALS
La probabilité de faillite calculée de CONVERT PHARMACEUTICALS sur 12 mois est de 0,4% (très faible). L'entreprise est active depuis 2017 et le Moniteur belge ne contient aucun signal d'insolvabilité ou d'avertissement. Aucun chiffre de comptes annuels traité n'est disponible ; cette conclusion repose uniquement sur les données du registre et du Moniteur belge.
| Active | 9 ans |
| Sites | 1 |
| Publications | 4 |
Estimation statistique fondée sur des sources publiques — pas un conseil de crédit ni une constatation. Comment calculons-nous cela ?
| Exercice | Type | Dépôt | Référence |
|---|---|---|---|
| 31-12-2024 | volledig | 26-06-2025 | 2025-00224144 |
| 31-12-2023 | volledig | 06-06-2024 | 2024-00115697 |
| 31-12-2022 | volledig | 08-06-2023 | 2023-00117666 |
| 31-12-2021 | volledig | 12-07-2022 | 2022-20182438 |
| 31-12-2020 | volledig | 22-06-2021 | 2021-23000593 |
| 31-12-2019 | volledig | 29-06-2020 | 2020-22200064 |
| 31-12-2018 | volledig | 02-07-2019 | 2019-26900236 |
| 31-12-2017 | volledig | 09-08-2018 | 2018-44700063 |
| NACE primaire | 72109 |
| Forme juridique | SA(014) |
| Date de constitution | 24-02-2017 |
| Status | Actif |
| Code postal | 4000 |
Parcelles liées à cette entreprise via ses adresses BCE (siège, unités d'établissement, succursales), croisées avec le plan parcellaire cadastral. Ceci montre où l'entreprise est active — pas un registre de propriété.
| Parcelle (capakey) | Région | Superficie | Bâtiments | Hauteur / ét. |
|---|---|---|---|---|
| 62814C0006/00G002 | Wallonie | 6 004 m² | — | — |
Une seule chronologie de tout ce qui est arrivé à cette entreprise — publications, événements d'insolvabilité et de cycle de vie, changements administratifs et comptes annuels déposés.
29-08-2025 1 administrateur nommé, 1 démissionnaire
- Brice Van Eeckhout — Directeur
- Paul Tulcinsky — Directeur
Détails techniques
{
"events": [
{
"kind": "board_snapshot",
"role": "bestuurder",
"person": null,
"reason": null,
"subkind": null,
"via_org": null,
"statutory": null,
"compensated": null,
"effective_date": null,
"evidence_quote": "",
"decharge_status": null,
"mandate_duration": null,
"rep_rotation_new_rep": null,
"rep_rotation_old_rep": null,
"effective_date_qualifier": null
},
{
"kind": "director_out",
"role": "directeur",
"person": {
"rrn": null,
"name": "Paul Tulcinsky",
"address": null,
"birth_date": null,
"profession": null,
"birth_place": null
},
"reason": "death",
"subkind": null,
"via_org": null,
"statutory": null,
"compensated": null,
"effective_date": "2025-02-20",
"evidence_quote": "Les Administrateurs prennent acte de la d\u00E9mission, en sa qualit\u00E9 d\u0027administrateur de la Soci\u00E9t\u00E9, avec effet au 20 f\u00E9vrier 2025, de Monsieur Paul Tulcinsky en raison de son d\u00E9c\u00E8s en date du 20 f\u00E9vrier 2025.",
"decharge_status": null,
"mandate_duration": null,
"rep_rotation_new_rep": null,
"rep_rotation_old_rep": null,
"effective_date_qualifier": "immediate"
},
{
"kind": "director_in",
"role": "directeur",
"person": {
"rrn": null,
"name": "Brice Van Eeckhout",
"address": null,
"birth_date": null,
"profession": null,
"birth_place": null
},
"reason": null,
"subkind": "successor_conditional",
"via_org": null,
"statutory": null,
"compensated": null,
"effective_date": "2025-05-15",
"evidence_quote": "\u00C0 la suite du d\u00E9c\u00E8s de Monsieur Paul Tulcinsky et de la vacance d\u0027un mandat d\u0027administrateur de Soci\u00E9t\u00E9, les Administrateurs d\u00E9cident de coopter, avec effet imm\u00E9diat, Monsieur Brice Van Eeckhout.",
"decharge_status": null,
"mandate_duration": {
"kind": "until_agm_year",
"value": "2026"
},
"rep_rotation_new_rep": null,
"rep_rotation_old_rep": "Paul Tulcinsky",
"effective_date_qualifier": "immediate"
},
{
"kind": "decharge_granted",
"role": "directeur",
"person": {
"rrn": null,
"name": "Brice Van Eeckhout",
"address": null,
"birth_date": null,
"profession": null,
"birth_place": null
},
"reason": null,
"subkind": null,
"via_org": null,
"statutory": null,
"compensated": null,
"effective_date": null,
"evidence_quote": "L\u0027assembl\u00E9e prend acte de la d\u00E9mission, en sa qualit\u00E9 d\u0027administrateur de la Soci\u00E9t\u00E9, avec effet au 20 f\u00E9vrier 2025, de Monsieur Paul Tulcinsky en raison de son d\u00E9c\u00E8s en date du 20 f\u00E9vrier 2025.",
"decharge_status": "granted",
"mandate_duration": null,
"rep_rotation_new_rep": null,
"rep_rotation_old_rep": null,
"effective_date_qualifier": null
}
],
"notary": {
"name": null,
"firm_city": null,
"firm_name": null,
"office_city": null,
"is_associated": false
},
"act_meta": {
"language": "mixed",
"pub_date": "2025-08-29",
"filing_date": "2025-08-05",
"act_kind_objet": "Objet de l\u0027acte:"
},
"decisions": [
{
"body": "conseil_d_administration",
"date": "2024-11-27",
"unanimous": null
},
{
"body": "enig_aandeelhouder_schriftelijk",
"date": "2025-07-01",
"unanimous": null
},
{
"body": "enig_aandeelhouder_schriftelijk",
"date": "2025-05-15",
"unanimous": true
},
{
"body": "algemene_vergadering",
"date": "2025-06-02",
"unanimous": true
}
],
"is_correction": false,
"subject_company": {
"kbo": "0671.828.631",
"name_full": "CONVERT PHARMACEUTICALS",
"legal_form": "SA"
},
"publication_proxy": {
"kind": "org",
"org_kbo": null,
"org_name": "Harvest Avocats",
"person_name": null,
"org_rep_person_name": null,
"person_role_at_subject": null
},
"co_filed_documents": [
"25109962"
],
"corrected_publication_numac": null
}29-08-2025 Transfert du siège social vers Liège
- Silversquare Guillemins - Esplanade Simone Veil 1, 4000 Liège
Détails techniques
{
"events": [
{
"kind": "zetel_transfer",
"seat_type": "siege_social",
"new_address": {
"raw": "Silversquare Guillemins - Esplanade Simone Veil 1, 4000 Li\u00E8ge",
"city": "Li\u00E8ge",
"region": "waals_gewest",
"street": "Esplanade Simone Veil",
"country": "BE",
"postcode": "4000",
"box_number": null,
"street_number": "1",
"locality_suffix": null
},
"old_address": null,
"effective_date": "2025-01-01",
"evidence_quote": "Le Conseil approuve la d\u00E9cision de d\u00E9m\u00E9nager le si\u00E8ge social de la soci\u00E9t\u00E9 \u00E0 Silversquare Guillemins - Esplanade Simone Veil 1, 4000 Li\u00E8ge \u00E0 compter du 1ier janvier 2025.",
"region_changed": false,
"is_statute_change": true,
"nationality_change": false,
"old_address_source": "inferred",
"statute_clause_text": null,
"statute_article_number": null,
"effective_date_qualifier": "absolute",
"statutaire_vs_werkelijke": null,
"linguistic_region_changed": false,
"court_jurisdiction_changed": false,
"effective_date_is_approximate": false
}
],
"notary": {
"name": null,
"firm_city": null,
"firm_name": null,
"office_city": null,
"is_associated": false
},
"act_meta": {
"language": "mixed",
"pub_date": "2025-08-29",
"filing_date": "2025-08-05",
"act_kind_objet": "Changement de si\u00E8ge, d\u00E9mission, cooptation et nomination d\u0027un administrateur"
},
"decision": {
"body": "conseil_d_administration",
"date": "2024-11-27",
"unanimous": null
},
"subject_company": {
"kbo": "0671.828.631",
"name_full": "CONVERT PHARMACEUTICALS",
"legal_form": "SA"
},
"publication_proxy": {
"kind": "org",
"org_kbo": null,
"org_name": "Harvest Avocats",
"person_name": null,
"org_rep_person_name": null,
"person_role_at_subject": null
},
"co_filed_documents": [
"Extrait du proc\u00E8s-verbal de la r\u00E9union du conseil d\u0027administration du 27 novembre 2024",
"Extrait de la r\u00E9solution \u00E9crite des administrateurs prise en date du 1er juillet 2025",
"Extrait des r\u00E9solutions \u00E9crites et unanimes des administrateurs prises en date du 15 mai 2025",
"Extrait du proc\u00E8s-verbal de l\u0027assembl\u00E9e g\u00E9n\u00E9rale ordinaire des actionnaires du 2 juin 2025"
]
}07-07-2025 Augmentation de capital de 952.497 € à 2.222.683 €
- €1.270.186 → €2.222.683
Détails techniques
{
"events": [
{
"kind": "capital_increase",
"after_eur": 2222683.0,
"delta_eur": 952497.0,
"before_eur": 1270186.0,
"share_emission": {
"agio_eur": null,
"share_form": "no_nominal_value",
"share_class": "A2",
"n_new_shares": 276086,
"with_new_shares": true,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": null,
"contribution_type": "apport_nature",
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "share_class_creation",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"share_emission": {
"agio_eur": null,
"share_form": null,
"share_class": null,
"n_new_shares": null,
"with_new_shares": false,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": null,
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "share_class_conversion",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"share_emission": {
"agio_eur": null,
"share_form": null,
"share_class": null,
"n_new_shares": null,
"with_new_shares": false,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": null,
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": 1.0,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
}
],
"notary": {
"name": "Peter VAN MELKEBEKE",
"firm_city": null,
"firm_name": "Berquin Notaires",
"office_city": "Bruxelles",
"is_associated": true
},
"act_meta": {
"language": "fr",
"pub_date": "2025-07-07",
"filing_date": "2025-07-03",
"act_kind_objet": "Objet de l\u0027acte:"
},
"decision": {
"body": "assembl\u00E9e_generale_extraordinaire",
"act_date": "2025-06-24",
"unanimous": null,
"under_authorized_capital": false,
"underlying_resolution_date": null
},
"bedrijfsrevisor": {
"waived": false,
"firm_kbo": null,
"firm_name": "CDP NICOLET \u0026 C\u00B0 SRL",
"ibr_number": null,
"mission_type": "apport_nature",
"individual_name": "Jean Nicolet"
},
"subject_company": {
"kbo": "0671.828.631",
"name_full": "CONVERT PHARMACEUTICALS",
"legal_form": "Soci\u00E9t\u00E9 anonyme",
"is_foreign_registered": false
},
"publication_proxy": {
"kind": "none",
"org_kbo": null,
"org_name": null,
"person_name": null,
"org_rep_person_name": null,
"person_role_at_subject": null
},
"co_filed_documents": [
"exp\u00E9dition du proc\u00E8s-verbal",
"procuration",
"texte coordonn\u00E9 des statuts",
"rapport de l\u0027organe d\u0027administration",
"rapport du r\u00E9viseur d\u0027entreprises"
],
"shareholders_after": [],
"share_classes_after": [
{
"n_shares": 1943712,
"class_name": "A1",
"capital_share_eur": null,
"voting_rights_per_share": 1.0
},
{
"n_shares": 276086,
"class_name": "A2",
"capital_share_eur": null,
"voting_rights_per_share": 1.0
}
]
}07-07-2025 Modification des statuts — traduction des statuts, coordination des statuts et refonte complète des statuts
Détails techniques
{
"notary": {
"name": "Peter VAN MELKEBEKE",
"firm_city": null,
"firm_name": "Berquin Notaires",
"office_city": "Bruxelles",
"is_associated": true
},
"act_meta": {
"language": "fr",
"pub_date": "2025-07-07",
"filing_date": "2025-07-03",
"act_kind_objet": "CAPITAL, ACTIONS, STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS)"
},
"decision": {
"body": "buitengewone_algemene_vergadering",
"act_date": "2025-06-24",
"unanimous": null
},
"statute_change": {
"kinds": [
"translation",
"coordination",
"full_restatement",
"targeted_amendment",
"legal_form_change",
"wvv_adaptation",
"name_change",
"object_change",
"duration_change",
"share_split",
"share_consolidation",
"share_class_creation",
"language_switch",
"warrant_exercise_capital_update",
"board_authorized_capital",
"governance_restructure",
"liquidation_preference_introduction",
"seat_region_change",
"other"
],
"scope": "full_restatement",
"trigger": "wvv_adaptation",
"language_after": "fr",
"language_before": "fr"
},
"bedrijfsrevisor": {
"firm_kbo": null,
"firm_name": "CDP NICOLET \u0026 C\u00B0 SRL",
"ibr_number": null,
"individual_name": "Jean Nicolet"
},
"subject_company": {
"kbo": "0671.828.631",
"name_full_after": "CONVERT PHARMACEUTICALS",
"legal_form_after": "Soci\u00E9t\u00E9 anonyme",
"name_full_before": "CONVERT PHARMACEUTICALS",
"current_zetel_raw": "Clos Chanmurly 13 4000 Li\u00E8ge",
"legal_form_before": "Soci\u00E9t\u00E9 anonyme"
},
"special_mandates": [
{
"holder_kbo": null,
"holder_name": "Harvest Legal",
"scope_categories": [
"kbo",
"btw"
],
"with_substitution": true
}
],
"articles_modified": [
{
"summary": "The article was replaced with new text defining the capital, share structure, and conversion rights for preferential shares.",
"new_text": " Le capital est fix\u00E9 \u00E0 deux millions deux cent vingt-deux mille six cent quatre-vingt-trois euros (2.222.683,00 EUR). Il est repr\u00E9sent\u00E9 par un million neuf cent quarante-trois mille sept cent douze (1.943.712) actions sans d\u00E9signation de valeur nominale, divis\u00E9es en actions ordinaires de cat\u00E9gorie A1 et actions de cat\u00E9gorie A2, ordinaires et pr\u00E9f\u00E9rentielles. Chaque action repr\u00E9sente 1/2.222.683\u00E8me",
"change_kind": "replaced",
"article_title": null,
"article_number": "5"
}
],
"governance_change": {
"organ_kind_after": null,
"organ_kind_before": null,
"admin_delegated_added": [
{
"name": "Adrien Lanotte",
"excluded_powers": []
},
{
"name": "Elise Hamesse",
"excluded_powers": []
},
{
"name": "Harvest Legal",
"excluded_powers": []
}
],
"representation_rule_after": null,
"co_signature_threshold_eur": null,
"representation_rule_before": null
},
"publication_proxy": {
"kind": "person",
"org_kbo": null,
"org_name": null,
"person_name": "Peter VAN MELKEBEKE",
"org_rep_person_name": null
},
"co_filed_documents": [
"une exp\u00E9dition du proc\u00E8s-verbal",
"une procuration",
"le texte coordonn\u00E9 des statuts",
"le rapport de l\u0027organe d\u0027administration \u00E9tabli en application de l\u0027article 7:155 du Code des soci\u00E9t\u00E9s et des associations",
"le rapport de l\u0027organe d\u0027administration",
"le rapport du r\u00E9viseur d\u0027entreprises \u00E9tabli en application des articles 7:179, \u00A71, deuxi\u00E8me alin\u00E9a et 7:197, \u00A71, deuxi\u00E8me alin\u00E9a du Code des soci\u00E9t\u00E9s et des associations"
],
"shareholder_rights": null,
"voorwerp_change_summary": null,
"capital_structure_change": {
"operations": [
"capital_increase_kind",
"share_class_creation"
],
"split_ratio": null,
"shares_after": 2222683,
"shares_before": 1270186,
"capital_after_eur": 2222683.0,
"capital_before_eur": 1270186.0,
"share_classes_after": [
{
"count": 1943712,
"label": "A1",
"rights_summary": "Ordinary shares",
"voting_per_share": 1.0
},
{
"count": 276086,
"label": "A2",
"rights_summary": "Preferential shares, convertible to A1",
"voting_per_share": 1.0
}
]
},
"coordinated_text_lineage": null
}Générez une note structurée et factuelle à partir de tous les signaux de ce dossier : risque, santé financière, structure de propriété, mandats et comparaison sectorielle.
| Dénomination légaleFR | CONVERT PHARMACEUTICALS |